{"id":62745,"date":"2023-09-18T23:29:23","date_gmt":"2023-09-19T03:29:23","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/abbvies-botox-meets-key-goals-in-2nd-platysma-prominence-study\/"},"modified":"2023-09-18T23:29:26","modified_gmt":"2023-09-19T03:29:26","slug":"abbvies-botox-meets-key-goals-in-2nd-platysma-prominence-study","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=62745","title":{"rendered":"AbbVie’s Botox Meets Key Goals in 2nd Platysma Prominence Study"},"content":{"rendered":"
\n

By Colin Kellaher<\/p>\n

<\/pre>\n
A second late-stage study of AbbVie’s antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging process that disrupts the neck, jawline and lower face.<\/p>\n
AbbVie’s Allergan unit on Monday said the Phase 3 study of Botox in the treatment of moderate-to-severe platysma prominence met all primary and secondary endpoints, with study results consistent with findings from a prior Phase 3 study.<\/p>\n
\n
Allergan said it will include the study data as part of a U.S. Food and Drug Administration regulatory submission it expects to file near the end of the year, adding that an FDA green light would make Botox the first and only neurotoxin for platysma prominence, which results from contraction of a superficial, flat muscle in the lower face and neck.<\/p>\n
Botox, which the FDA first approved in 1989 for a pair of rare eye muscle disorders, is currently FDA-approved for a raft of cosmetic and therapeutic indications. AbbVie posted combined Botox cosmetic and therapeutic revenue of more than $2.8 billion for the first half of 2023.<\/p>\n
<\/pre>\n
Write to Colin Kellaher at colin.kellaher@wsj.com<\/p>\n
<\/pre>\n<\/p><\/div>\n<\/div>\n
Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
By Colin Kellaher A second late-stage study of AbbVie’s antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging process that disrupts the neck, jawline and lower face. AbbVie’s Allergan unit on Monday said the Phase 3 study of Botox in the treatment of moderate-to-severe platysma prominence met all […]<\/p>\n","protected":false},"author":1,"featured_media":1898,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-62745","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"\nAbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study | iFintechWorld<\/title>\n<meta name=\"description\" content=\"By Colin Kellaher A second late-stage study of AbbVie's antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=62745\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"By Colin Kellaher A second late-stage study of AbbVie's antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=62745\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-19T03:29:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-19T03:29:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=62745#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=62745\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"AbbVie’s Botox Meets Key Goals in 2nd Platysma Prominence Study\",\"datePublished\":\"2023-09-19T03:29:23+00:00\",\"dateModified\":\"2023-09-19T03:29:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=62745\"},\"wordCount\":201,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=62745#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=62745\",\"url\":\"https:\/\/ifintechworld.com\/?p=62745\",\"name\":\"AbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-09-19T03:29:23+00:00\",\"dateModified\":\"2023-09-19T03:29:26+00:00\",\"description\":\"By Colin Kellaher A second late-stage study of AbbVie's antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=62745#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=62745\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=62745#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie’s Botox Meets Key Goals in 2nd Platysma Prominence Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study | iFintechWorld","description":"By Colin Kellaher A second late-stage study of AbbVie's antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=62745","og_locale":"en_US","og_type":"article","og_title":"AbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study | iFintechWorld","og_description":"By Colin Kellaher A second late-stage study of AbbVie's antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging","og_url":"https:\/\/ifintechworld.com\/?p=62745","og_site_name":"iFintechWorld","article_published_time":"2023-09-19T03:29:23+00:00","article_modified_time":"2023-09-19T03:29:26+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=62745#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=62745"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"AbbVie’s Botox Meets Key Goals in 2nd Platysma Prominence Study","datePublished":"2023-09-19T03:29:23+00:00","dateModified":"2023-09-19T03:29:26+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=62745"},"wordCount":201,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=62745#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=62745","url":"https:\/\/ifintechworld.com\/?p=62745","name":"AbbVie's Botox Meets Key Goals in 2nd Platysma Prominence Study | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-09-19T03:29:23+00:00","dateModified":"2023-09-19T03:29:26+00:00","description":"By Colin Kellaher A second late-stage study of AbbVie's antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=62745#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=62745"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=62745#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie’s Botox Meets Key Goals in 2nd Platysma Prominence Study"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/62745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62745"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/62745\/revisions"}],"predecessor-version":[{"id":62746,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/62745\/revisions\/62746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/1898"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}